Zoledronic Acid: A Review of its Use in the Treatment of Paget's Disease of Bone

Authors: Keating, Gillian M.; Scott, Lesley J.

Source: Drugs, Volume 67, Number 5, 2007 , pp. 793-804(12)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

The third-generation, nitrogen-containing bisphosphonate zoledronic acid (Aclasta^®) is approved in the EU for the treatment of Paget's disease of bone. Results of well designed trials show that a single intravenous dose of zoledronic acid 5mg is effective and well tolerated in the treatment of Paget's disease of bone. A single intravenous dose of zoledronic acid was associated with a significantly higher therapeutic response rate and a more rapid reduction in bone turnover than that achieved with 60 days of oral risedronic acid. Moreover, biochemical remission was sustained after 24 months of follow-up in zoledronic acid recipients. Preliminary results suggest that zoledronic acid is a cost-effective option in Paget's disease of bone. Thus, zoledronic acid is an important first-line treatment for Paget's disease of bone.

Keywords: Adis Drug Evaluations; Paget's disease; Zoledronic acid

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2007-01-01